We have conducted an in silico data base search for and cloned a novel G-protein-coupled receptor (GPCR) named TG1019. Dot and Northern blotting analyses showed that transcripts of the novel GPCR were expressed in various tissues except brain, and the expression was more intense in liver, kidney, peripheral leukocyte, lung, and spleen than in other tissues. By GTP␥S binding assay using the TG1019-G␣ i1 -protein fusion expressed in insect cells, eicosanoids, and polyunsaturated fatty acids such as 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE), 5(S)-hydroperoxy-6E,8Z, 11Z,14Z-eicosatetraenoic acid, and arachidonic acid were identified to exhibit agonistic activities against TG1019. 5-oxo-ETE was the most potent to enhance the specific binding by 6-fold at a maximum effect dose of submicromolar to micromolar order with an ED 50 value of 5.7 nM. Conversely, polyunsaturated fatty acids such as docosahexaenoic acid and eicosapentaenoic acid showed antagonistic activities against TG1019. In Chinese hamster ovary cells transiently expressing TG1019, the forskolin-stimulated production of cAMP was inhibited up to ϳ70% by 5-oxo-ETE, with an IC 50 value of 33 nM. This inhibition was sensitive to pretreatment of the cells with pertussis toxin.
and lipids into activation of G-proteins for effectors to generate intracellular second messengers. They are divided into distinct subfamilies according to their various types of ligands and according to sequence homologies.
Recently, vigorous in silico search for and cloning of novel genes with sequence motifs characteristic of GPCRs have outpaced identification of novel endogenous ligands, accumulating a group of putative GPCR genes (by the criterion of sequence similarity), for which the ligands are not known (4, 5) . These GPCRs, commonly known as orphans, are likely to mediate heretofore unidentified signaling and might represent a fruitful source for new drugs, judging from the precedents established by the numerous GPCRs used as targets of important drugs in use today (6) . There have been several reports on identification of cognate ligands for orphan GPCRs by using the recombinant orphan receptors as the specific sensors in bioassays (7) (8) (9) .
Here, we describe discovery of a novel G i/o -coupled receptor, tentatively denoted as TG1019, whose ligands were identified to be eicosatetraenoic acids and polyunsaturated fatty acids, including 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE), 5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE), 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-HETE), and arachidonic acid. Arachidonic acid is metabolized into biologically and pharmacologically important mediators, which include prostaglandins, leukotrienes, prostacyclins, thromboxanes, and eicosatetraenoic acids such as 5(S)-HPETE, 5(S)-HETE, and 5-oxo-ETE (10) . Although GPCRs for the preceding four kinds of mediators have been already known (11) , there have been no reports on GPCR for the eicosatetraenoic acids.
EXPERIMENTAL PROCEDURES

Materials-5-oxo-ETE, 5(S)-HPETE, 5Z
,8Z,11Z-eicosatrienoic acid (Mead acid), 5(R)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(R)-HETE), 5(S)-hydroxy-6E,8Z,11Z-eicosatrienoic acid (5(S)-HETrE), 11Z,14Z,17Z-eicosatrienoic acid, 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA), 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid (EPA), and 8Z,11Z,14Z-eicosatrienoic acid (dihomo-␥-linolenic acid) were purchased from Cayman Chemical Company (Ann Arbor, MI). All of the other lipids used in this study were obtained from BIOMOL Research Laboratories, Inc. (Plymouth, PA). Rabbit anti-human G␣ i1 , anti-human G␣ q , and anti-human G␣ s antisera were from Calbiochem. Pertussis toxin and fetal bovine serum were from Sigma Chemical Co. Rolipram and forskolin were from Tocris (Avonmouth, United Kingdom) and Nacalai Tesque (Japan), respectively. [␣- 32 
P]dCTP and [
35 S]GTP␥S were from Amersham Biosciences. DMEM/F-12 media for cell culture was from Invitrogen.
Data Base Searching for GPCR-We created a consensus amino acid sequence (IYSIVFVVGLLGNALVIWVLLRHKKMRTVTNIYILNLAI-X 26 LCKIVSFLYXVNMYASIFTLTAISIDRYLAIVHPLX 65 FX 33 RVVRM-ILVVVVVFAICWLPYHIX 14 AX 10 LAYLNSCINPIIYAFLSKNFR; the amino acid sequence is shown in one-letter designation, in which X represents any amino acid) of a GPCR family recognizing peptide ligands by aligning the GPCRs registered in the GPCR data base (12), * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBank TM /EBI Data Bank with accession number(s) AB083055. ‡ Both authors contributed equally to this work. § To whom correspondence should be addressed. Tel.: 81-48-433-8065; Fax: 81-48-433-8159; E-mail: t-ohnuki@tanabe.co.jp. 1 The abbreviations used are: GPCR, G-protein-coupled receptors; 5-oxo-ETE, 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5(S)-HPETE, 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; arachidonic acid, 5Z,6Z,11Z,14Z-eicosatetraenoic acid; Mead acid, 5Z,8Z,11Z-eicosatrienoic acid; 5(Ϯ)-HETE, 5(Ϯ)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5(S)-HETE, 5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5(R)-HETE, 5(R)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5(S)-HETrE, 5 (S)-hydroxy-6E,8Z,11Z-eicosatrienoic acid; eicosatrienoic  acid, 11Z,14Z,17Z-eicosatrienoic acid; DHA, 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid; EPA, 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid; aa, amino acid(s); nt, nucleotide(s); KRH buffer, Krebs-Ringer Hepes buffer; PG, prostaglandin; LT, leukotriene; GTP␥S, guanosine 5Ј-O-(thiotriphosphate); CHO, Chinese hamster ovary; TM, transmembrane domain; DMEM, Dulbecco's modified Eagle's medium. using BlockMaker (13) . Putative orphan GPCR sequences were searched for among public data bases by tblastn (14) using the consensus sequence as a query.
Cloning and Sequencing of TG1019 Gene-Specific oligonucleotide primers were designed on the basis of the sequence of GenBank TM accession number AC013396.3: a sense primer, 5Ј-ttctcagtggctgcgagaatgctgat-3Ј corresponding to nucleotides (nt) 97,735-97,760 of AC013396.3 and an antisense primer, 5Ј-acccacctgagtcctgccagtgcttt-3Ј corresponding to nt 96,299 -96,324 of AC103396.3. A PCR with these primers was performed on a human cDNA library (Human Universal Quick-Clone cDNA, CLONTECH) by using Advantage 2 Polymerase Mix (CLONTECH). The amplification conditions were as follows: 30 s at 94°C, 30 cycles of 30 s at 94°C, 30 s at 64°C, and 2.5 min at 72°C, and then 2.5 min at 72°C. The amplification gave a DNA fragment of ϳ1.5 kb, which was purified by agarose gel electrophoresis and cloned into pGEM-T Easy Vector (Promega Corp.), resulting in pGEM-TG1019. The cloned DNA was sequenced on both strands with ThermoSequenase Cycle sequencing kit (USB Corp., Cleveland, OH), and DNA sequencer Long Read IR 4200 (Aloka, Japan). We read all parts of the cloned sequence at least three times each.
Dot Blot and Northern Hybridization-Human Multiple Tissue Expression (MTE) Array2 (CLONTECH), a nylon membrane on which poly(A) RNAs extracted from various human tissues and cell lines were dotted, and Human 12-Lane MTN blot (CLONTECH) were used for analysis of distribution of TG1019 expression in human tissues and for Northern hybridization analysis, respectively. [␣-
32 P]dCTP-labeled probe was prepared by random priming of the 0.9-kb fragment corresponding nt 371-1270 encoding a large part of TG1019 ( Fig. 1 ) with Prime-a-Gene labeling system (Promega Corp.). The DNA fragment was generated by PCR using a sense primer (5Ј-tttggccctcttcatcttctgcat-3Ј), an antisense primer (5Ј-ccctgcactttcagcttccctatg-3Ј), and pGEM-TG1019 as a template. Hybridization was conducted as described in the manufacturer's protocols. The membranes were prehybridized in ExpressHyb hybridization solution (CLONTECH) supplemented with 0.1 mg of salmon testes DNA (Sigma) per milliliter at 65°C for 30 min and hybridized with the 32 P-labeled probe in ExpressHyb solution supplemented with 0.1 mg of salmon testes DNA (Sigma) per milliliter at 65°C for 14 h. In the case of dot blotting hybridization, 6 g of human COT-1 DNA (Roche Molecular Biochemicals) per milliliter and 0.2ϫ SSC were also added to the hybridization solution. The bolt of MTE Array2 was washed four times in 2ϫ SSC containing 1% SDS at 65°C and twice in 0.1ϫ SSC containing 0.5% SDS at 55°C for 20 min. The MTN blot was washed four times in 2ϫ SSC containing 0.05% SDS at room temperature and twice in 0.1ϫ SSC containing 0.1% SDS at 50°C for 20 min. The membranes were exposed to an imaging plate (BAS-III, Fujifilm, Japan) and analyzed by using a BAS2000 imaging analyzer (Fujifilm).
Construction of Baculovirus Expression Vectors-Identification of a ligand for the orphan GPCR was conducted by measuring ligand-dependent GTP␥S binding to G␣-protein. We constructed an assay system using fused GPCR-G␣-protein expressed in insect cells by referring to the reports of Wenzel-Seifert and Seifert (15) and Bahia et al. (16) .
cDNAs of G␣ i1 with a mutation of Cys 351 3 Ile, G␣ q , and G␣ sL were amplified by PCR with the primers designed on the basis of the registered sequences for G␣ i1 (GenBank TM accession number AF055013), G␣ q (GenBank TM U43083), and G␣ sL (GenBank TM X04408) genes and templates of Marathon-Ready cDNA Brain (CLONTECH) for G␣ i1 (Cys 351 3 Ile), Marathon-Ready cDNA Prostate (CLONTECH) for G␣ q , and Marathon-Ready cDNA Bone marrow (CLONTECH) for G␣ sL , respectively. The mutation in G␣ i1 , known to enhance the GTP␥S binding activated by ligands as compared with the native (16), was introduced by replacing the nucleotide in the antisense primer used. CpoI and BamHI restriction recognition sequences were attached to the sense and antisense primers, respectively. The amplified DNAs were cloned into pGEM-T Easy vector and sequenced to be confirmed the same as the registered sequences. The plasmids obtained above were cut with NotI and BamHI, and the DNA fragments of the coding regions for G␣ i1 (Cys 351 3 Ile), G␣ q , and G␣ sL were purified by agarose gel electrophoresis and inserted into a baculovirus vector plasmid pVL1392 (BD PharMingen). The DNA fragment encoding TG1019 was amplified by using 5Ј-agatctatgttgtgtcaccgtggtggccagc-3Ј as a sense primer, 5Ј-aagcttcggtccgccctgggaggagccttccttttcca-3Ј as an antisense primer, and pGEM-TG1019 as a template, and cloned into pGEM-T Easy. By the PCR reaction, a stop codon of the TG1019 gene was replaced by a Gly codon, and a CpoI site was added to the 3Ј-end of the gene. The resultant plasmid was cut with NotI and CpoI, and the TG1019 gene was inserted into pVL1392 carrying each of the G␣ genes, generating pVL1392/TG1019-G␣ i1 (Cys 351 3 Ile), pVL1392/TG1019-G␣ q , and pVL1392/TG1019-G␣ sL , respectively. Two amino acids, -Gly-Pro-, were inserted between TG1019 and each of the G␣-proteins.
GTP␥S Binding Assay-Transfection of Sf9 cells with the baculovirus expression vectors and preparation of the recombinant virus were carried out with a BaculoGold kit (BD PharMingen) or a Bac-N-Blue transfection kit (Invitrogen) as recommended by the manufacturer. The Sf9 cells grown in a dish of 10-cm diameter were transfected by the recombinant virus and cultured at 27°C for 4 days. The cells were harvested in 3.6 ml of 20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml pepstatin, and 2 g/ml aprotinin and homogenized with a Teflon homogenizer. The homogenate was centrifuged at 600 ϫ g for 10 min, and the supernatant was subjected to ultracentrifugation at 50,000 ϫ g for 20 min. The precipitate was suspended in 450 l of a reaction buffer containing 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, and 10 mM MgCl 2 . The membrane suspension was diluted to 16 ml with the reaction buffer and added to 6 l of 10 mM GDP just before use in the reaction. Expression of the fused TG1019-G␣-proteins was confirmed by Western blotting analysis using the antisera against the respective species of G␣ subunits.
Reactions of GTP␥S binding were done in 200 l of reaction mixture consisting of 160 l of the diluted membrane suspension, 20 l of 5 nM [ 35 S]GTP␥S (5 nCi/l), and 20 l of a sample to be tested: The radioisotope and sample were prepared in the reaction buffer. After incubation at 30°C for 60 min, the reaction mixture was filtrated through UniFilter-96GF/B (Packard), and the filter was washed three times with the ice-cold reaction buffer, and dried 60°C for 30 min. The radioactivities that remained on the filter were measured by liquid scintillation counting. The specific binding was defined as the remainder of the radioactivity bound on membrane after incubation with 500 pM Transient Expression of TG1019 in CHO Cells and Cyclic AMP Assays-The full-length cDNA encoding TG1019 on pGEM-TG1019 was subcloned into a NotI site of pcDNA3.1 expression vector (Invitrogen), resulting in pcDNA3.1-TG1019. CHO cells (1 ϫ 10 6 cells) were seeded in a dish of 6-cm diameter (Sumilon, Japan) and cultured in DMEM/F-12 supplemented with 10% fetal bovine serum at 37°C for 20 h in a humidified atmosphere of 5% CO 2 . The cells were transfected by 5 g of pcDNA3.1-TG1019 DNA or pcDNA3.1 for a mock experiment with LipofectAMINE (Invitrogen), as recommended by the manufacturer. After incubation for 24 h, the cells were harvested with cell-dissociation buffer (enzyme-free/phosphate-buffered saline-based, Invitrogen) and washed twice with Krebs-Ringer Hepes (KRH) buffer (124 mM NaCl, 5 mM KCl, 1.25 mM MgSO 4 , 1.45 mM CaCl 2 , 1.25 mM KH 2 PO 4 , 25 mM HEPES (pH 7.4), and 8 mM glucose). After incubation at 37°C for 30 min with KRH buffer supplemented with 25 M rolipram, 90 l of the cell suspension (5-7.5 ϫ 10 4 cells/well) was seeded in a 96-well plate. Then, 90 l of KRH buffer containing 1 M forskolin and 2ϫ final concentration of 5-oxo-ETE was added, and the plates were incubated at room temperature for 10 min. The cells were lysed by adding 20 l of lysis buffer 1A (a component of the cAMP enzyme immunoassay system, Amersham Biosciences), and 80 l of the cell lysate was used for measurement of cAMP produced during the incubation with the kit, as recommended by the manufacturer. To examine effect of pertussis toxin treatment on the cAMP production, the transfected CHO cells were cultured in DMEM/F-12 supplemented with 10% fetal bovine serum for 20 h and then in the culture medium supplemented with 100 ng of pertussis toxin per ml for 4 h. to have seven transmembrane domains by HMMTOP analysis (17) .
RESULTS
Data Base Search and Cloning of TG1019 -
We designed the primers based on the registered DNA sequence and cloned a 1462-bp sequence containing the open reading frame coding for the putative GPCR from the cDNA library by PCR. Fig. 1 shows the nucleotide and deduced amino acid sequences of the cloned cDNA. The nucleotide sequence had differences of four nucleotides at positions of nucleotide (nt) 487 (A 3 G), nt 771 (A 3 G), nt 1022 (A 3 C), and nt 1038 (A 3 G) as compared with the sequence registered in GenBank TM accession number AC013396.3, which resulted in the changes of amino acids encoded at positions of amino acids (aa) 150 (Asp 3 Gly), aa 245 (Lys 3 Glu), and aa 334 (Thr 3 Ala) (Fig. 1) . To investigate whether these differences were due to errors of PCR or nucleotide polymorphisms, we carried out cloning an ApaI fragment (nt 283-1173) (Fig. 1) by PCR using 5Ј-tccctctgcctttaccactgtggg-3Ј as a sense primer, 5Ј-gtaggagctctcgtcgctcactg-3Ј as an antisense primer, and MarathonReady cDNA library (human fetal spleen, CLONTECH), constructed by using a mixture of mRNA preparations from 29 persons as a template, and sequenced the amplified DNA fragments. We conducted two separate PCR reactions and analyzed a total of 10 clones, that is six and four clones obtained by each of the reactions. Regarding the nucleotide positions of nt 487, 771, and 1038, all clones sequenced gave the nucleotides identical to the registered sequence, i.e. A at nt 487, 771, and 1038, whereas at nt 1022, five clones (two and three clones from each PCR) had C as the clone shown in Fig. 1 , and five clones (four and one clone from each PCR) had A as the registered sequence. Therefore, it would be conceivable that the sequence registered in GenBank TM accession number AC013396.3 was accurate and that the position of nt 1022 exhibited a nucleotide polymorphism. For further studies, we used the clone with the sequence depicted in Fig. 1 , otherwise stated below. 
FIG. 5. Effect of 5-oxo-ETE on forskolin-stimulated cAMP production in CHO cells transiently expressing the eicosanoid GPCR, TG1019
, and its sensitivity to pretreatment by pertussis toxin. CHO cells were transiently transfected by pcDNA3.1-TG1019 (E, f) or pcDNA3.1 (q) and subjected to stimulation of cAMP production by forskolin with (f) or without (E, q) pretreatment with 100 ng of pertussis toxin per milliliter. Amounts of cAMP accumulated were measured as described under "Experimental Procedures." Production of cAMP is expressed as a percentage of control in the absence of 5-oxo-ETE. The data represent the mean Ϯ S.E. of three independent experiments in triplicate. In the absence of 5-oxo-ETE (control), CHO We tentatively denoted the novel GPCR as TG1019. TG1019 displayed a low homology with orphan GPCRs, HM74 (18) (41%, identities ϭ 121 aa/294 aa) and GPR31 (19) (33%, identities ϭ 104 aa/306 aa), but not a significant homology with GPCRs for which ligands have been identified, as far as searched by BLAST.
Tissue Distribution of Expression of TG1019 Gene-Dot-blotting hybridization analysis showed that the gene encoding TG1019 was expressed in various tissues except brain, although somewhat more intense signals were observed in mRNA from kidney and liver ( Fig. 2A) . Northern hybridization identified three hybridizing bands with molecular lengths of 6.5, 3.3, and 1.8 kb (Fig. 2B) . The transcripts of 6.5 and 3.3 kb were expressed in liver and kidney and in skeletal muscle, respectively, whereas the 1.8-kb transcript was major in peripheral leukocyte, lung, placenta, small intestine, spleen, thymus, colon, and heart, and also found in skeletal muscle, liver, and kidney. In Northern blot analysis, hybridization bands of peripheral leukocyte, lung, liver, kidney, and spleen seemed to be more intense than those of the other tissues (Fig. 2B) .
Identification of Ligands for TG1019 -At first, we estimated how good our GPCR-G␣-protein fusion system worked by using human -1 (data not shown) .
We screened a library of natural bioactive compounds and their relatives for ligands of TG1019 using the TG1019-G␣ fusions. It was found that some kinds of eicosanoids and unsaturated fatty acids activated binding of GTP␥S to the membrane fraction expressing TG1019-G␣ i (Cys 351 3 Ile). The most potent ligand with agonistic activity was 5-oxo-ETE, which enhanced the specific binding of GTP␥S by 5-to 6-fold at 0.1-1 M concentration (Fig. 3A) . In contrast, 5-oxo-ETE did not significantly activate the binding of GTP␥S to TG1019-G␣ sL and TG1019-G qa , although a small degree (ϳ40%) of activation of TG1019-G␣ q could be detected by 5-oxo-ETE (Fig. 3A) as well as by the other active eicosanoids and unsaturated fatty acids (data not shown). Another GPCR-G ia fusion, UDP-glucose receptor-G␣ i1 (Cys 351 3 Ile), was not activated by 5-oxo-ETE at all (Fig. 3A) . The identified agonists included 5-oxo-ETE, 5(S)-HPETE, arachidonic acid, Mead acid, 5(Ϯ)-HETE, and 5(S)-HETrE (Fig. 3B) . Their rank order of the potencies for the activation was 5-oxo-ETE (maximal activation ϭ 600 Ϯ 26% of basal, ED 50 ϭ 5.7 Ϯ 2. Screening for Antagonists against TG1019 -Antagonists against TG1019, if found, would be useful for elucidation of functions of the GPCR. We screened lipid compounds for the antagonists using the GTP␥S binding assay. The GPCR was activated with 0.1 M 5-oxo-ETE, achieving the submaximal activation.
4Z,7Z,10Z,13Z,16Z,19Z-Docosahexaenoic acid (DHA), 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid (EPA), dihomo-␥-linolenic acid, and 11Z,14Z,17Z-eicosatrienoic acid were found to antagonize the ligand against TG1019 with the following IC 50 values: DHA, 1.6 Ϯ 0.2 M; EPA, 6.0 Ϯ 1.2 M; dihomo-␥-linolenic acid, 3.7 Ϯ 0.7 M; and 11Z,14Z,17Z-eicosatrienoic acid, 5.1 Ϯ 0.6 M (Fig. 4) .
Transient Expression of TG1019 in CHO Cells and cAMP Signaling-In the GTP␥S binding assay, TG1019 was markedly activated by the eicosanoids and polyunsaturated fatty acids only when fused to G␣ i -protein but not to G␣ s or G␣ q . This result suggested that TG1019 would probably be coupled to a type of G␣ i/o -protein. To confirm this idea, we transiently overexpressed TG1019 in CHO cells and tested the effect of 5-oxo-ETE on forskolin-stimulated cAMP production. In the cells transfected by the expression plasmid encoding TG1019 (pcDNA3.1-TG1019), the cAMP production was clearly inhibited by 5-oxo-ETE, as compared with that in the cells transfected by pcDNA3.1 (mock) (Fig. 5) . The distinct inhibition (ϳ30% inhibition) was observed at 10 nM 5-oxo-ETE, and the inhibition dose-dependently increased to ϳ70% at 1 ϳ 3 M 5-oxo-ETE with IC 50 value ϭ 33 Ϯ 19 nM. Pretreatment of the cells transfected by pcDNA3.1-TG1019 with pertussis toxin completely abolished the inhibition of the forskolin-stimulated cAMP production by 5-oxo-ETE. This result supported the idea that TG1019 would be coupled to a G␣ i/o -protein.
The amino acid sequence of TG1019 shown in Fig. 1 had the differences of three amino acids (aa 150, Asp 3 Gly; aa 245, Lys 3 Glu; and aa 334, Thr 3 Ala) in comparison with the sequence deduced from the nucleotide sequence registered in GenBank TM accession number AC013396.3, as described under "Data Base Search and Cloning of TG1019." To investigate whether or not the differences affected its biological function, we cloned the ApaI fragment of 0.9 kb encoding the same amino acid sequence as the registered one by PCR and constructed the expression plasmid by substituting the ApaI fragment of pcDNA3.1-TG1019 with the newly cloned fragment. Forskolinstimulated cAMP accumulation was inhibited in CHO cells transiently expressing the receptor with the registered sequence like in those expressing TG1019 with the sequence of Fig. 1 (data not shown) . Therefore, the changes of amino acids would not affect the biological function of TG1019. DISCUSSION We described in this paper the cloning of a novel G-proteincoupled receptor, tentatively named as TG1019, and identification of the eicosanoids and polyunsaturated fatty acids such as 5-oxo-ETE, 5(S)-HPETE, and arachidonic acid as its ligands by using the GPCR-G␣ fusion system. The novel GPCR would be coupled to a G␣ i/o -protein, because the marked enhancement of GTP␥S binding to TG1019-G␣-protein by the ligands was observed only when TG1019 was fused to G␣ i1 (Cys 351 3 Ile). This coupling was confirmed by the observation of the inhibition of forskolin-stimulated cAMP production by 5-oxo-ETE in the cells transiently overexpressing TG1019. The expression of TG1019 was detected in various tissues except brain; preferential expression was observed in peripheral leukocyte, lung, spleen, liver, and kidney by Northern blotting analysis.
The compounds with the agonistic activity, included 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE), 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE), 5Z,8Z,11Z,14Z-eicosatetraenoic acid (arachidonic acid), 5Z,8Z,11Z-eicosatrienoic acid (Mead acid), 5(Ϯ)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(Ϯ)-HETE), 5(S)-hydroxy-6E,8Z,11Z-eicosatrienoic acid (5(S)-HETrE), 5,8,11-eicosatriynoic acid, and 5Z,8Z-eicosadienoic acid, and the rank order of their potencies was 5-oxo-ETE Ͼ Ͼ 5-HPETE Ͼ arachidonic acid ϭ 5-HETE ϭ Mead acid ϭ 5-HETrE ϭ 5,8,11-eicosatriynoic acid ϭ 5Z,8Z-eicosadienoic acid. The common structures of these agonists, i.e. minimal requirements for exhibiting the agonistic activity against TG1019, are a length of carbon chain (20 carbons) and being unsaturated between C-8 and C-9. It would be apparent that the functional groups attached at C-5 are critical for the potency of the agonistic activity, on comparison of 5-oxo-ETE, 5-hydroperoxy-ETE (5-HPETE), and 5-hydroxy-ETE (5-HETE).
The term eicosanoids collectively refers to the oxidized arachidonic acid derivatives (23) . Arachidonic acid is converted to prostaglandins and thromboxanes by cyclooxygenase (prostaglandin endoperoxide synthase); leukotrienes via 5-HPETE by 5-lipoxygenase; to lipoxins via 15-HPETE by 15-lipoxygenase; and 12-HPETE by 12-lipoxygenase (24). 5-HPETE can be reduced by lipid peroxidases such as glutathione peroxidase to 5-HETE (25, 26) , which is finally oxidized to 5-oxo-ETE by 5(S)-hydroxyeicosanoid-specific dehydrogenase (27) . Eicosanoid receptors recognizing prostaglandins D 2 , E 2 , and F 2␣ ; prostacyclin; thromboxane A 2 ; and leukotriene B 4 ; respectively, have been cloned and vigorously analyzed because of the importance of their implicated biological functions such as inflammation, blood clotting, and control of vascular tone (11, 24, 28) . All of these eicosanoid receptors are categorized to GPCR. This is the first report to describe the GPCR (TG1019), which was activated by the eicosatetraenoic acids and polyunsaturated fatty acids, including 5-oxo-ETE, 5-HPETE, 5-HETE, and arachidonic acid.
The amino acid sequence of TG1019 was aligned with those of the human prostanoid GPCRs, PG D2 receptor (Fig. 6, DP ) (29) , PG E2 receptor subtype 1 (EP1) (30), subtype 2 (EP2) (31), subtype 3 (EP3) (32), subtype 4 (EP4) (33) , PG F2␣ receptor (FP) (34) , prostacyclin receptor (IP) (35) , and thromboxane A 2 receptor (TP) (36) (Fig. 6) . Among the prostanoid receptors other than TG1019, the apparent homologies are found in the transmembrane (TM) domains and the third extracellular loop, although the rest of the intra-and extracellular loops are not conserved. Motif sequences for each of the conserved regions could be derived as follows: SPAXXXXMFXXGXVGNL-LALXXL in TM I; FLXLVXGLXXTDLLGXLXXXP in TM II; LCXXXXXXMXFFGLXXLLXXXAMAV in TM III; RXXXXX-LXXVXAXXLXXXLLPLL in TM IV; GXGXYXXQXPGTWCFI in the third extracellular loop; LFAXLGLLLXXAXXLC-NXXXXXXLXR in TM V; LXXXMXVXXVC(W/S)LPLXV in TM VI; and LRXASXNQILDPWVYILLRKAV in TMVII. The boldface letters represent amino acids conserved in all of the prostanoid receptors aligned in Fig 6. The conserved amino acids in the prostanoid receptor are also found in TG1019: 103 5-oxo-ETE exhibited the most potent agonistic activity against TG1019. This eicosanoid is known as a potent chemotactic factor of eosinophils and neutrophils (37) (38) (39) (40) . O'Flaherty et al. (41, 42) , and O'Flaherty and Rossi (43) had revealed that the chemotactic activity would be mediated through a pertussis toxin-sensitive GPCR. As a separate line of interesting studies on 5-oxo-ETE and the derivatives, Ghosh and Myers (44, 45) had identified 5-oxo-ETE and 5-HETE as mitogenic as well as anti-apoptotic factors in prostate cancer cells. TG1019 might be responsible for mediating those biological functions of 5-oxo-ETE and 5-HETE.
We found that some kinds of fatty acids, including DHA, EPA, 11Z,14Z,17Z-eicosatrienoic acid, and dihomo-␥-linolenic acid, had the antagonistic activities against TG1019. These antagonists might be useful to elucidate the biological functions of TG1019.
